The drug discovery field is increasingly powered by AI-driven platforms such as AlphaFold 3, XtalPi, Insilico Medicine’s Pharma.AI suite, and Nanyang Biologics’ Vecura, which accelerate target identification, molecule design, and preclinical candidate selection.

XtalPi collaborates with more than 80 partners and contributes to projects like Paxlovid development, while Insilico Medicine’s Pharma.AI suite (including PandaOmics and Chemistry42) speeds up preclinical candidate identification.

AI in drug discovery aids literature search, target identification, molecule design, and validation, with AlphaFold 3 helping predict structures and interactions and its ecosystem reaching millions of researchers worldwide.

ICON is integrating AI into trial operations through Meridian, a centralized monitoring environment, complemented by Orbis, an agentic AI platform that coordinates end-to-end trial workflows under human oversight.

Overall AI adoption across discovery, clinical research, and manufacturing is expanding, with potential savings exceeding $50 billion annually in R&D costs, while scalable deployment hinges on ongoing development and partnerships.

In clinical research, agentic AI systems automate repetitive, compliance-heavy tasks, improve trial execution, and maintain audit trails, with tools like Medable’s Agent Studio and eCOA capabilities driving efficiency gains and strong patient engagement.

Manufacturing AI tools, including Aizon for anomaly detection and batch optimization, Veeva Vault for quality and regulatory workflows, and Aragen Life Sciences for AI-enabled lead optimization and data analytics, are boosting yield and regulatory compliance across CROs, CMOs, and biopharma partners.

Medidata, part of Dassault Systèmes, offers cloud platforms used by many of the world’s top pharma companies to support data management, analytics, and trial operations.

AI adoption in life sciences is becoming mainstream, blending off-the-shelf platforms with custom AI solutions to enhance efficiency, speed, and predictive capabilities across the discovery, development, and manufacturing stages.

Enterprises are deploying AI across functions such as finance, legal, HR, and IT to streamline routine work and boost productivity, with examples including Zai Lab’s use of Microsoft Copilot and internal AI agents on Dify.ai.

Prominent players and platforms highlighted include Isomorphic Labs/Google DeepMind’s AlphaFold ecosystem, XtalPi, Insilico Medicine, and Nanyang Biologics, illustrating broad collaboration and internal tool development across firms.

Owkin analyzes pathology data for biomarker discovery and trial optimization, a service leveraged by eight of the top ten pharmaceutical companies.